Stay updated on Pembrolizumab in Refractory Meningioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.

Latest updates to the Pembrolizumab in Refractory Meningioma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThis update changes the ClinicalTrials.gov page’s displayed revision/version from v3.5.0 to v3.5.3, indicating an internal platform release without altering the study information presented.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check49 days agoChange DetectedRevision label updated to v3.5.0; the previous v3.4.3 label was removed.SummaryDifference0.1%

- Check64 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check85 days agoChange DetectedThe visible change is a minor revision label updated from v3.4.1 to v3.4.2; no alterations to the study content, eligibility criteria, or essential page functionality are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check92 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check93 days agoChange DetectedThe page shows a minor version update from v3.4.0 to v3.4.1. There are no observed changes to core study content, eligibility criteria, or outcomes; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Refractory Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.